Liver Disease in Pregnancy: What’s New

Carla W. Brady

Liver disease in pregnancy may present as a disorder that is unique to pregnancy or as an acute or chronic liver disease occurring coincidentally in pregnancy. Hepatic diseases that are unique to pregnancy include hyperemesis gravidarum; preeclampsia/eclampsia; the syndrome of hemolysis, elevated liver enzymes, and low platelets; intrahepatic cholestasis of pregnancy; and acute fatty liver of pregnancy. Acute and chronic forms of primary hepatic disorders that are seen in pregnancy include viral hepatitis, autoimmune hepatitis, nonalcoholic fatty liver disease, and cirrhosis. Because of the need to consider both maternal and fetal health, there are special considerations for the implementation of diagnostic strategies and pharmacologic therapies for liver disease that occurs in pregnancy. An understanding of the pathogenesis and expression of liver diseases in pregnancy has been evolving, and various diagnostic and prognostic tools have been studied in order to determine noninvasive approaches to identifying and staging of such diseases. Investigations have also been underway to evaluate the safety and utility of existing and new therapeutic agents that previously were thought to not be compatible with pregnancy. This review will explore updates in the epidemiology, diagnosis, and management of various liver diseases seen in pregnancy. (Hepatology Communications 2020;4:145-156).

There are increasing data about the prevalence, natural history, and management of liver diseases in pregnancy and in women of childbearing age. Rates of liver disease are increasing among adolescents and young adults. Data from the National Health and Nutrition Examination Survey across 1988-1994 and 1999-2012 demonstrated a significant increase in the prevalence of chronic liver disease in women between 15 and 39 years of age, noting chronic liver disease rates in this subpopulation of 10.4% during 1988 to 1994, 26.1% during 1999 to 2004, and 24.9% during 2007 to 2012. (1) As the most common liver disease in this study cohort, nonalcoholic fatty liver disease (NAFLD) was noted to have a prevalence of 6.8% during 1988 to 1994, 20.3% during 1999 to 2004, and 18.1% during 2007 to 2012. The prevalence of alcohol-related liver disease also rose significantly, whereas the prevalence of hepatitis C virus (HCV) infection decreased during the study periods. From 2000 to 2015, death rates for chronic liver disease and cirrhosis in women aged 25 to 44 years increased by 18%. (2) Another study that examined trends in liver disease among hospital admissions in women who were pregnant during 2002 to 2010 demonstrated that liver diseases unique to pregnancy and gallstone disease were the two most common hepatic diseases, occurring at rates of 7.18 per 1,000 pregnancy hospitalizations and 4.65 per 1,000 pregnancy hospitalizations, respectively. (3) The rates of liver disease per each 3-year interval over the entire 9-year study period increased for all examined liver diseases (hepatitis B, hepatitis C, gallbladder disease, biliary tract disease, alcohol-related liver disease, and various liver disorders that are unique to pregnancy), and the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) was observed as the most costly liver disease seen during pregnancy hospitalizations. Such epidemiologic data suggest that women who are pregnant and women of childbearing age are at risk of significant morbidity and mortality due to liver disease.

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AFLP, acute fatty liver of pregnancy; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HELLP, hemolysis, elevated liver enzymes, and low platelets; HG, hyperemesis gravidarum; ICP, intrahepatic cholestasis of pregnancy; kPa, kilopascal; MELD, Model for End-Stage Liver Disease; MTCT, mother to child transmission; NAFLD, nonalcoholic fatty liver disease; TIPS, transjugular portosystemic shunt; UDCA, ursodeoxycholic acid.

Received September 1, 2019; accepted December 10, 2019.
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep4.1470

Potential conflict of interest: Nothing to report.
A number of physiologic changes occur throughout pregnancy in order to sustain the growth and development of the fetus. This can lead to expected changes in some laboratory findings, inclusive of minimal to slight decreases in hepatic transaminases and elevations in alkaline phosphatase levels (Table 1).\(^4\) Despite these findings, there is a 3\% to 5\% incidence of liver enzyme abnormalities in pregnancy.\(^5\) Due to the need to consider the health of the mother and fetus, a number of special considerations must be accounted for in the diagnosis and management of hepatic disorders in pregnancy (Table 2).\(^6,7\) Initial assessments of liver enzyme abnormalities in pregnancy should begin with noninvasive testing, which can include laboratory and radiographic studies. Radiographic investigations for liver disease in women who are pregnant should begin with ultrasound. If subsequent radiographic assessment is required, magnetic resonance imaging without contrast is an acceptable modality in the setting of pregnancy. Use of gadolinium should be avoided in pregnancy due to its association with teratogenicity, and the use of computed tomography in pregnancy must be carefully weighed against the risks of ionizing radiation to the fetus. Invasive testing, such as liver biopsy and endoscopy, may be considered if required to facilitate appropriate management of the presenting liver disorder.

This review will provide updates on the management of liver diseases that are unique to pregnancy and primary liver diseases that are concurrent with pregnancy.

### Liver Diseases That Are Unique to Pregnancy

#### HYPEREMESIS GRavidarum

Hyperemesis gravidarum (HG) is seen earlier than other liver diseases that are unique to pregnancy, typically presenting in the first trimester and resolving by the twentieth week of gestation. Occurring in about 0.3\% to 2\% of pregnancies, HG presents as intractable nausea and vomiting with subsequent dehydration, weight loss, electrolyte imbalance, and nutritional deficiency.\(^8\) Liver involvement is seen in 50\% to 60\% of patients with HG.\(^9\) Biochemical changes include elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, which are typically mildly elevated but have been observed to rise to as high as 1,000 in some patients with HG.\(^10\) Jaundice is rare, occurring more commonly in severe cases of HG. The etiology of elevated liver enzymes in HG is unclear but has been proposed to involve liver cell injury due to multiple factors, including dehydration, starvation, and placental-derived cytokines, including tumor necrosis factor alpha.\(^11,12\) It is noted that liver enzyme levels return to normal levels after resolution of HG, and thus there are no long-term sequelae of HG on liver-related health.

HG treatment involves administration of intravenous fluid, antiemetic therapy, and vitamin and mineral

### ARTICLE INFORMATION:

From the Division of Gastroenterology, Duke University Medical Center, Durham, NC.

### ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Carla W. Brady, M.D., M.H.S.
Duke University Medical Center
DUMC 3913
Durham, NC 27710
E-mail: carla.brady@duke.edu
Tel.: +1-919-681-4044
supplementation. Thiamine and folic acid supplementation are particularly emphasized, and metoclopramide, promethazine, and ondansetron are anti-emetic therapies that are considered as compatible with pregnancy. Dietary modification should focus on consumption of small, frequent, low-fat meals with high carbohydrate content. Enteral or parenteral nutrition can be cautiously considered in severe HG cases.

### HYPERTENSIVE DISORDERs OF PREGNANCY

Hypertensive disorders of pregnancy that involve the liver include preeclampsia/eclampsia and the HELLP syndrome. Preeclampsia is seen in about 3% to 5% of pregnancies, and it is defined by the presence of new onset hypertension with a systolic blood pressure of ≥140 mm Hg and a diastolic blood pressure of ≥90 mm Hg measured on at least two occasions that are 4 to 6 hours apart and proteinuria of greater than 300 mg/day. Eclampsia occurs in about 1.4% of pregnancies; it is defined by the development of generalized seizures during preeclampsia. HELLP syndrome occurs in 0.2% to 0.6% of pregnancies and complicates 10% to 20% of cases of preeclampsia/eclampsia. Whereas preeclampsia is typically described as occurring after the twentieth week of gestation, HELLP syndrome is predominantly considered as occurring in the third trimester between weeks 28 and 36 of gestation. In 30% of cases, HELLP syndrome presents in the early postpartum period.

HELLP syndrome has been viewed as representing one presentation on a spectrum of clinical manifestations of preeclampsia/eclampsia. Other manifestations of preeclampsia can involve hypertension in the absence of proteinuria, and in this clinical scenario, the presence of end-organ injury in the setting of gestational hypertension can help to define preeclampsia. Due to the dilemma of distinguishing HELLP syndrome along the spectrum of preeclampsia/eclampsia, two diagnostic criteria for HELLP syndrome have been established. The Tennessee Classification categorizes HELLP syndrome as complete HELLP syndrome or partial HELLP syndrome, and the Mississippi Triple Class System divides HELLP syndrome into three classes (Table 3). Both of these classification systems define subtypes of HELLP based on the severity of observed thrombocytopenia, liver enzyme elevations, and hemolysis.

The pathophysiology of preeclampsia/eclampsia and HELLP syndrome is not well understood and likely

---

**TABLE 2. DIAGNOSTIC MODALITIES FOR LIVER DISEASE IN PREGNANCY AND LACTATION**

| Modality           | Pregnancy Considerations                  | Lactation Considerations                  | Other Issues                                                                 |
|--------------------|-------------------------------------------|-------------------------------------------|-----------------------------------------------------------------------------|
| Ultrasound         | Acceptable modality                       | Acceptable modality                       | No available data on contrasted ultrasound in pregnancy and lactation       |
| CT                 | Risk of ionizing radiation exposure to fetus during pregnancy | Acceptable modality                       | Greatest risk of radiation exposure is at 8 to 15 weeks of gestation         |
| MRI                | Acceptable modality when performed without contrast | Acceptable modality with and without contrast | Oral and iodinated contrast not teratogenic                                |
| Liver biopsy       | Can be performed in pregnancy             | Acceptable modality                       | Less than 1% of iodinated contrast is excreted in breast milk                |
| Transient elastography | Not approved by the FDA for use in pregnancy | Not contraindicated in lactation          | Gadolinium is associated with teratogenicity; crosses the placenta and is found in amniotic fluid and fetal circulation. Less than 0.04% is excreted into breast milk |
| Endoscopy          | Upper endoscopy is acceptable in pregnancy and typically recommended to occur in the second trimester | Acceptable modality with consideration of compatibility of sedating medications with lactation | Ensure proper informed consent with discussion about fetal risks             |

Abbreviations: CT, computed tomography; FDA, U.S. Food and Drug Administration; IVC, inferior vena cava; MRI, magnetic resonance imaging.
involves a combination of immunologic maladaptation, chronic placental ischemia, an increased maternal inflammatory response to trophoblasts, and increases in inflammatory cytokines. Vasospasm is a feature of preeclampsia that likely results from hemoconcentration in conjunction with imbalances between vasoconstrictors (thromboxane A2 and endothelins) and vasodilators (prostacyclin and nitric oxide), and it may be a contributor to liver injury, which can involve fibrin deposition, periportal hemorrhage, necrosis or infarction of hepatocytes, and microvesicular fat infiltration. Severe liver involvement can lead to hepatic hematoma or rupture. Thrombocytopenia is thought to result from increases in platelet activation and consumption.

The observation of imbalances in thromboxane A2 and prostacyclin have led to the use of low-dose aspirin in the management of hypertensive disorders of pregnancy. Low-dose aspirin preferentially inhibits thromboxane A2. Meta-analyses and systematic reviews have demonstrated reductions in the risks of preeclampsia, fetal growth restriction, and fetal death with use of low-dose aspirin, and thus it is recommended that low-dose aspirin (81 mg daily) is instituted between 12 weeks and 28 weeks of gestation in patients with high-risk factors for preeclampsia.

Other medical therapy includes administration of intravenous magnesium to prevent seizures, antihypertensive therapy to maintain systolic blood pressures below 160 mm Hg and diastolic blood pressures below 100 mm Hg, and intravenous dexamethasone to improve platelet counts. Such pharmacologic intervention has been described as The Mississippi Protocol. Elevations in aminotransferase and lactate dehydrogenase levels may persist for up to 48 hours postpartum, but ongoing hepatic, renal, or hematologic complications beyond 72 hours postpartum signal potential life-threatening complications that require urgent therapy. Surgical intervention is required for enlarging subcapsular hematomas or hepatic rupture. Hepatic rupture can also be managed with hepatic arterial embolization. Liver transplantation has been performed in cases of hepatic decompensation despite medical therapy and in cases of hepatic rupture or hematoma. The only curative therapy for preeclampsia/eclampsia and HELLP syndrome is delivery of the fetus.

**ACUTE FATTY LIVER OF PREGNANCY**

Acute fatty liver of pregnancy (AFLP) is a rare disorder that occurs in about 1:7,000 to 1:15,000 pregnancies. Typically occurring in the third trimester, it involves maternal microvesicular fat deposition in the liver that leads to hepatic decompensation with potential for hepatic failure. Maternal mortality is 10% to 15%, and fetal mortality is up to 20%.

It is thought that AFLP is caused by inherited deficiencies of enzymes that are involved in the mitochondrial metabolism of fetal fatty acids. Impairment in fatty acid oxidation in the fetus and placenta can lead to increases in the levels of intermediate products of metabolism that accumulate in the placenta and maternal blood, leading to maternal hepatotoxicity. The most investigated fatty acid oxidation defect that is thought to contribute to AFLP is a deficiency in long chain 3-hydroxyacyl-coenzyme A-dehydrogenase (LCHAD), which is a part of the mitochondrial trifunctional protein (MTP). G1528C and E474Q mutations of MTP are thought to be the cause of LCHAD deficiency and development of AFLP.

The diagnosis of AFLP may be challenging as features of its presentation can present similarly in preeclampsia and HELLP syndrome, both of which have been observed to develop in mothers who are heterozygous for fetal fatty acid oxidation defects and pregnant with homozygous fetuses. The classic description of clinical findings in AFLP includes abdominal pain, nausea, vomiting, fatigue, and anorexia; biochemical

---

**TABLE 3. CLASSIFICATION SYSTEMS FOR HELLP SYNDROME**

| HELLP Class       | Mississippi Classification | Tennessee Classification |
|-------------------|----------------------------|--------------------------|
| Class 1 (severe)  | AST or ALT ≥70 IU/L, LDH ≥600 IU/L, Platelet count ≤5 × 10^9/L | AST ≥70 IU/L, LDH ≥600 IU/L or bilirubin ≥1.2 mg/dL |
| Class 2 (moderate)| AST or ALT ≥70 IU/L, LDH ≥600 IU/L, Platelet count 50-100 × 10^9/L | N/A |
| Class 3 (mild)   | AST or ALT ≥40 IU/L, LDH ≥600 IU/L, Platelet count 100-150 × 10^9/L | N/A |
| Partial HELLP syndrome | Presence of severe preeclampsia plus one of the following: ELP, EL, HEL, LP | |

Abbreviations: EL, elevated liver enzymes; ELP, elevated liver enzymes and low platelets (missing hemolysis); HEL, hemolysis and elevated liver enzymes; LDH, lactate dehydrogenase; LP, low platelets; N/A, not applicable.
abnormalities include aminotransferase elevations up to 20 times the upper limit of normal and hyperbilirubinemia. Proteinuria, a diagnostic feature of preeclampsia/eclampsia, can also occur in AFLP. Coagulopathy with prolongation in prothrombin times can also present in both disorders, but this is due to hepatic dysfunction in AFLP and due to derangements in consumption in preeclampsia/eclampsia. Thus, the presentation of AFLP is often suggestive of liver dysfunction, whereas the presentations of preeclampsia/eclampsia and HELLP syndrome are typically more suggestive of significant liver injury with less impact on hepatic synthetic function.

In AFLP, ultrasound can demonstrate heterogeneity of the liver parenchyma in a manner that is consistent with fatty infiltration. Liver biopsy can confirm the presence of microvesicular fat deposition in the peri-central zone with periportal sparing. Such fat deposition is confirmed with Oil Red O staining that should be performed on fresh-frozen sections. Liver biopsy is not typically required for diagnosis, and the associated coagulopathy of AFLP may preclude performance of liver biopsy. The diagnosis of AFLP can be facilitated by use of the Swansea criteria, which are combined clinical, laboratory, and radiographic features for which the diagnosis can be made if at least six of the features are present (Table 4). The Swansea criteria have been demonstrated to have 100% sensitivity, 57% specificity, 85% positive predictive value, and 100% negative predictive value in the diagnosis of AFLP.

AFLP management involves prompt delivery of the fetus. Despite delivery, laboratory and clinical abnormalities may persist for up to a week postpartum; rarely, there can be progression to liver failure that requires liver transplantation. Fetuses born to mothers with AFLP should be monitored closely as they are at risk of developing liver failure, cardiomyopathy, nonketotic hyperglycemia, myopathy, and neuropathy. Recurrence of AFLP can occur in mothers, and up to 25% of children born to mothers with AFLP will carry fatty acid oxidation defects. Thus, affected patients should be screened.

### INTRAHEPATIC CHOLESTATIS OF PREGNANCY

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disease. Typically presenting in the second or third trimester of pregnancy, the prevalence of ICP is 0.1% to 2%.

Epidemiologic data have indicated that it occurs with higher prevalence in South American and Scandinavian countries, and additional risk factors for it include advanced maternal age, multiparity, and a previous history of cholestasis with oral contraceptive use. The classic symptom of ICP is pruritus, but epigastric pain, fatigue, anorexia, and jaundice have also been observed. The typical laboratory finding in ICP is an elevation in bile acid levels. AST and ALT levels range from normal levels to 10 times to 20 times normal.

A number of adverse outcomes are associated with ICP, including preterm birth, meconium-stained amniotic fluid, fetal distress, and stillbirth. Given the severity of these complications, the identification and utilization of predictive markers for ICP have been the focus of numerous published investigations. Earlier data from a large Swedish cohort demonstrated that the likelihood of the development of meconium-stained fluid, spontaneous preterm birth, and fetal asphyxia increased by 1% to 2% for every μmol/L of bile acids. Further analysis in this study demonstrated that such complications developed when bile acid levels were greater than 40 μmol/L. A more recent prospective case-control study from the United Kingdom demonstrated similar adverse events in women with ICP whose serum...
bile acids were above 40 μmol/L, with a weaker yet significant association of higher ALT levels with these adverse outcomes. Seven of the 10 patients with ICP whose pregnancies were complicated by stillbirth were also diagnosed with other pregnancy-related conditions, including preeclampsia and gestational diabetes, and the median gestational age at stillbirth was 36 weeks. These observations raised concern regarding the possible presence of other concurrent conditions that could influence outcomes of severe presentations of ICP, and it provided data to support consideration for delivery at 37 weeks of gestation in ICP. More recent data from a systematic review on perinatal outcomes in ICP identified an increased risk of stillbirth in ICP when serum bile acid levels are 100 μmol/L or higher. In this study, transaminase and bilirubin levels were not significant predictors of negative obstetric outcomes; however, increased rates of concurrent preeclampsia and gestational diabetes were seen in women with ICP compared to those without ICP, thus supporting previously identified concerns regarding the presence of other concurrent pregnancy-related conditions that could influence outcomes of severe presentations of ICP. The reason for fetal distress and stillbirths in ICP has not been fully elucidated, but observations of fetal tachyarrhythmia with atrial flutter and left ventricular dysfunction in fetuses of women with ICP provide concern for a cardiac source of these adverse events. Earlier clues of this include observations of toxic effects of bile acids on the myocardium of rats, but the pathophysiology of such toxicity is still under investigation. Recent data have also demonstrated an association of ICP with later development of hepatobiliary cancer, cardiovascular disease, and immune-related disease, including diabetes mellitus and thyroid disease. However, more studies are needed to elucidate the potential mechanisms for and strength of these associations.

Historically, the recommended treatment for ICP has been ursodeoxycholic acid (UDCA) at a dose of 10-15 mg/kg/day. ICP is thought to be due to a genetic mutation in bile salt transport across the transport membrane. The most common of these mutations is an adenosine triphosphate-binding cassette transporter B4 (ABCB4) mutation that encodes the multidrug resistance protein 3, which is a major transporter of phospholipids across the canalicular membrane into bile. Other mutations include the ABCB11 gene mutation, which is a mutation in the bile salt export pump (BSEP). It is thought that UDCA may increase placental bile transporters and increase BSEP expression. It has been shown to significantly reduce pruritus and reduce ALT and bile acid levels. However, more recent data from a multicenter, randomized, placebo-controlled trial investigating the effect of UDCA on perinatal outcomes concluded that UDCA does not significantly reduce the incidence of fetal death, preterm delivery, or fetal distress. Studies are ongoing to determine if there is pharmacologic intervention for ICP that will significantly reduce the incidence of adverse outcomes. At this time, appropriate delivery planning with consideration for delivery by 37 weeks of gestation is the intervention with clearly demonstrated benefit in obstetric outcomes for pregnancies affected by ICP.

Primary Liver Diseases That Are Concurrent With Pregnancy

HEPATITIS B

The clinical presentation of hepatitis B virus (HBV) infection in pregnancy is similar to the course of HBV infection in patients who are not pregnant. Although many such patients may be asymptomatic, nausea, vomiting, jaundice, and abdominal pain can be seen, particularly in acute HBV infection. However, obstetric outcomes are not significantly affected by HBV infection. Mother to child transmission (MTCT) and early childhood acquisition of HBV infection are modes of transmission in 50% of persons worldwide who develop chronic HBV infection. The presence of hepatitis B e antigen positivity and levels of hepatitis B viremia are the two most significant maternal risk factors for MTCT of hepatitis B. Hepatitis B immunoprophylaxis has been shown to significantly reduce the rate of MTCT of HBV infection, but immunoprophylaxis failures of 8% to 10% have been observed. Immunoprophylaxis consists of administration of hepatitis B immunoglobulin and hepatitis B vaccination within the first 12 hours after birth and subsequent scheduled administration.
of hepatitis B vaccination at 1–2 months of age and again at 6 months of age. In order to further reduce the risk of MTCT, American Association for the Study of Liver Diseases (AASLD) guidance on hepatitis B recommends antiviral therapy for mothers with HBV DNA levels of greater than 200,000 IU/mL.\(^\text{(56)}\) Whereas lamivudine, telbivudine, and tenofovir have been shown to be compatible with pregnancy, tenofovir is a preferred antiviral therapy due to its potency and lower likelihood of resistance. Breastfeeding is not contraindicated in cases where immunoprophylaxis has been administered, and due to observations of low levels of antiviral agents in breast milk, AASLD guidance does not recommend against breastfeeding in mothers who are on antiviral therapy.

**HEPATITIS C**

It is observed that the worldwide prevalence of HCV infection is 8%, and the prevalence in the United States is 1% to 2.5%.\(^\text{(57,58)}\) Recent data on a large cohort of U.S. women demonstrated increases in acute HCV infection in women of childbearing age during 2006 to 2014, and this observed increased incidence is thought to be related to the observed rise in injection drug use among this population cohort.\(^\text{(59)}\) MTCT transmission of HCV is 5% to 6% in cases of HCV monoinfection but can rise to as high as 22% in cases of co-infection with human immunodeficiency virus (HIV). Most presentations of HCV infection in women who are pregnant are presentations of chronic asymptomatic infection. Maternal outcomes of HCV infection are similar to HCV outcomes in patients who are not pregnant. However, there are conflicting data about obstetrical outcomes. Although some data have suggested that HCV infection does not affect obstetrical outcomes, other data have indicated associations of HCV infection with gestational diabetes, preterm delivery, low birth weight, requirements for neonatal intensive care, and the presence of ICP.\(^\text{(60,61)}\) No HCV immunoprophylaxis exists, and the mode of delivery of fetuses born to mothers with HCV infection should be based on obstetrical indications. However, it is recommended that fetal scalp monitoring is avoided due to reports of an increased risk of HCV transmission with this peripartum mode of monitoring.\(^\text{(62)}\)

Current HCV therapy consists of direct-acting antiviral therapies for which safety data in pregnancy and lactation are lacking. Thus, HCV therapy is not recommended in women who are pregnant or breastfeeding. However, recently presented conference data on a phase 1 study of ledipasvir/sofosbuvir in women who were pregnant and had HCV infection demonstrated achievement of rapidly undetectable HCV viral loads during pregnancy and sustained virologic response without significant adverse events.\(^\text{(63)}\) A recent case report of HCV therapy in a woman who was pregnant and had controlled HIV infection revealed a successful 6-week treatment with sofosbuvir alone that was followed by a 6-week course of sofosbuvir and velpatasvir.\(^\text{(64)}\) The infant born to this patient was without birth defects and was HCV negative at birth. Recent guidance statements from AASLD and the Infectious Diseases Society of America have emphasized a recommendation for universal HCV screening in women who are pregnant.\(^\text{(65)}\) The United States Preventive Services Task Force recently issued a draft statement that recommends screening for hepatitis C in all adults 18 to 79 years of age.\(^\text{(66)}\) Public comment regarding this recommendation has been solicited, and a final recommendation statement is currently pending. Establishment of this recommendation in clinical practice would support the existing societal recommendations for universal HCV screening in women who are pregnant.

**AUTOIMMUNE HEPATITIS**

Autoimmune hepatitis (AIH) activity is variable in women who are pregnant. Flares can be seen during pregnancy in 20% of women who are pregnant and can occur postpartum in 30% to 50%.\(^\text{(67)}\) Flares occur more commonly in women with AIH who are not on therapy and in women who experienced an AIH flare in the year before pregnancy. It is not well understood as to why some women will have AIH flares either during pregnancy or postpartum, but it is believed that changes in immune tolerance and the effect of hormone concentrations on immunologic responses may influence the likelihood of pregnancy-related AIH flares.\(^\text{(68)}\) Compared to women with AIH but with no cirrhosis, women with AIH-related cirrhosis are more likely to have pregnancies that are complicated by lower birth rates, higher rates of prematurity and need for neonatal intensive care, maternal hepatic decompensation, and need for liver transplantation and death.\(^\text{(69)}\)
Due to the potential for negative health outcomes associated with antepartum and postpartum flares, it is important that AIH activity is monitored closely and is well controlled before and during pregnancy and in the early postpartum period. Standard AIH treatment consists of corticosteroids and azathioprine, although it is noted that mycophenolate mofetil is an acceptable alternative agent if standard therapy is not tolerated. Despite the lack of meta-analyses and systematic reviews on AIH therapy in pregnancy, observational data about the use of corticosteroids and azathioprine in other immunologic diseases support the use of these therapies in AIH. It is recommended that women with AIH who become pregnant continue on an immunosuppression regimen throughout their pregnancies that allowed them to achieve stable liver function before pregnancy. Azathioprine is an acceptable alternative to mycophenolate use in women with AIH who are pregnant and in women who are contemplating pregnancy.

NAFLD

There are emerging data on the epidemiology, natural history, and clinical manifestations of NAFLD in pregnancy. It is estimated that the incidence of NAFLD in women of childbearing age is 10%. NAFLD is considered as a hepatic manifestation of the metabolic syndrome and is an endpoint of a complex combination of adipose tissue dysfunction with increased lipolysis and insulin resistance, defects in hepatic clearance of lipids, de novo hepatic lipogenesis, and lipotoxicity with oxidative stress and mitochondrial dysfunction. In the first two thirds of pregnancy, maternal hyperphagia and increases in lipogenesis lead to increased fat stores, whereas maternal catabolism in the third trimester leads to enhanced adipose tissue lipolysis with increased levels of free fatty acids and glycerol that are metabolized and re-esterified for the production of triglycerides, including very low-density lipoproteins. These changes in lipid metabolism as well as observations of pregnancy-related insulin resistance may foster a metabolic milieu that predisposes to the development of NAFLD and its associated comorbid conditions in pregnancy. Data have demonstrated that sonographic evidence of hepatic steatosis is predictive of the development of gestational diabetes mellitus and dysglycemia with impaired glucose tolerance and impaired glucose fasting. Other data have demonstrated an association of gestational diabetes mellitus with increased odds of subsequent NAFLD development in middle age. Adverse obstetric outcomes, including increased odds of preeclampsia, cesarean section, preterm birth, and low birth weight, are associated with NAFLD in women who are pregnant. These observations suggest a need for careful prepregnancy and interpregnancy planning, with careful query of possible factors in personal or family histories that are potential markers for metabolic syndrome as well as the need for postpartum assessments for metabolic syndrome in women with pregnancies that have been complicated by states of metabolic disarray, such as obesity, gestational diabetes mellitus, and preeclampsia.

CIRRHOSIS AND PORTAL HYPERTENSION

Pregnancy in cirrhosis has been reported to occur at a rate of 45 cases of cirrhosis per 100,000 childbearing women. This lower likelihood of pregnancy in women with cirrhosis is related to hypothalamic–pituitary dysfunction in cirrhosis that leads to amenorrhea and anovulation. In pregnancy, portal pressures increase due to plasma volume expansion and compression of the inferior vena cava during the second and third trimesters, and this pregnancy-related rise in portal pressures can augment the expression of complications of portal hypertension, which include ascites and varices.

Data are evolving regarding the incidence of medical and obstetrical complications of cirrhosis and portal hypertension. Historically, rates of bleeding from esophageal varices in pregnancy were reported to be as high as 30% with a risk of variceal hemorrhage increasing to 50% to 78% in the setting of preexisting varices. However, more recent data from the United States Nationwide Inpatient Sample database have observed rates of variceal hemorrhage of 5% in women with cirrhosis who were pregnant, and recent data from the Swedish Medical Birth Register and Swedish National Patient Register identified only one case of bleeding esophageal varices in 103 pregnancies in women with cirrhosis. Reported obstetrical complications in women who are pregnant have included increased rates of low birth weight, placental abruption, preterm delivery, and cesarean section.
Endoscopy as screening for varices is recommended in women with cirrhosis who are pregnant and should be performed during the second trimester because organogenesis has occurred by that stage of pregnancy. Management of varices in pregnancy is similar to management of varices in patients who are not pregnant. If variceal band ligation is pursued for esophageal varices, this should continue with a goal of eradication of varices as in patients who are not pregnant. Although there have been reported associations of beta blockers with intrauterine growth retardation and neonatal bradycardia, nonselective beta blocker therapy can be used as variceal bleeding prophylaxis in pregnancy. Nadolol has low protein binding and low rate of excretion and is less favored than propranolol, which is thought to be compatible with pregnancy. Historically, there have been concerns about the safety of transjugular portosystemic shunt (TIPS) insertion during pregnancy, mostly due to concerns about radiation risks. Data on TIPS insertion in pregnancy are limited mostly to case reports and case series. Although one such case series reported one fetal death that was not related to TIPS, other data have suggested that TIPS insertion can occur without maternal or fetal mortality. Ascites and hepatic encephalopathy can be managed in pregnancy similar to how such cirrhosis-related complications are managed in patients who are not pregnant.

Future Directions: Noninvasive Testing and Prognostic Models

In recent years, significant advances have been made in the development and implementation of noninvasive tests and scoring systems for the diagnosis, staging, and prediction of outcomes of liver diseases. Multiple investigations have evaluated whether such noninvasive testing can be predictive of outcomes of liver disease in pregnancy. The Model for End-Stage Liver Disease (MELD), MELD-sodium, United Kingdom End-Stage Liver Disease (UKELD), and Child-Pugh scores were evaluated in a cohort of 29 women with cirrhosis who were pregnant, and higher MELD (greater than or equal to 10) and UKELD scores (greater than or equal to 47) at conception were identified as significant predictors of liver-related adverse events, such as variceal hemorrhage, hepatic encephalopathy, and the development of significant ascites. In this cohort, it was also observed that a platelet count before conception of $110 \times 10^9$ cells/L or less had 78% sensitivity and 89% specificity in predicting the presence of varices on screening endoscopy performed during the second trimester of pregnancy. A more recent investigation of the albumin–bilirubin score and the AST to platelet ratio index determined that these measures in preconception were predictive of live birth and of the ability of pregnancies in women with chronic liver disease and cirrhosis to progress beyond 37 weeks of gestation. Investigators in Germany performed transient elastography on healthy women who were pregnant and on women with pregnancy-related liver disease (preeclampsia and ICP). They observed that liver stiffness increased in healthy women who were pregnant across pregnancy (mean kilopascal [kPa] score of 4.5 kPa in the second trimester to mean kPa score of 6.0 kPa in the third trimester); a liver stiffness score of greater than 8 was seen in 6% and greater than 12.5 kPa was seen in 1.5% of healthy women who were pregnant. Liver stiffness scores declined after delivery. Mean liver stiffness scores were significantly higher in preeclampsia (17.9 kPa) and in ICP (6.9 kPa) than in healthy women who were pregnant. It is noted that transient elastography is currently not approved by the U.S. Food and Drug Administration for use in pregnancy. Such noninvasive testing in pregnancy needs further study but may offer future opportunities for lower risk assessments of the severity of liver disease in women who are pregnant.

The successful management of liver disease in pregnancy requires a multidisciplinary approach with close collaboration between internists, hepatologists, and obstetricians. Evolving data have been helpful in expanding insights into the impact of liver disease on maternal and fetal health. Efforts are underway to explore newer diagnostic and therapeutic approaches to such diseases.

REFERENCES

1) Doycheva I, Watt KD, Rifa G, Abou Mrad R, Lopez R, Zein NN, et al. Increasing burden of chronic liver disease among adolescents and young adults in the USA: a silent epidemic. Dig Dis Sci 2017;62:1373-1380.

2) Centers for Disease Control and Prevention. QuickStats: death rates for chronic liver disease and cirrhosis, by sex and age group - National Vital Statistics System, United States, 2000 and 2015. MMWR Morb Mortal Wkly Rep 2017;66:1031.
3) Ellington SR, Flowers L, Legardy-Williams JK, Jamieson DJ, Kouris AP. Recent trends in hepatic diseases during pregnancy in the United States, 2002-2010. Am J Obstet Gynecol 2015;212:524.e1-524.e7.

4) Baq Y, Zarka O, Bréchot J, Mariotte N, Vol S, Tichet J, et al. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. Hepatology 1996;23:1030-1034.

5) Ch'ng CL, Morgan M, Hainsworth I, Kingham JG. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut 2002;51:876-880.

6) Committee on Obstetric Practice. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2017;130:210-e216. Erratum in: Obstet Gynecol 2018;132:786.

7) Tran TT, Ahn J, Reau NS. ACG clinical guideline: liver disease and pregnancy. Am J Gastroenterol 2016;111:176-194. Erratum in: Am J Gastroenterol 2016;111:1668.

8) Kallen B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur J Obstet Gynecol Reprod Biol 1987;26:291-302.

9) Hepburn IS, Schade RR. Pregnancy-associated liver disorders. Dig Dis Sci 2008;53:2334-2358. Erratum in: Dig Dis Sci 2008;53:2836.

10) Conchillo JM, Pijnenborg JM, Peeters P, Stockbrügger RW, Fevery J, Koek GH. Liver enzyme elevation induced by hyperemesis gravidarum: aetiology, diagnosis and treatment. Neth J Med 2002;60:374-378.

11) Morali GA, Braverman DZ. Abnormal liver enzymes and ketonuria and hyperemesis gravidarum. A retrospective review of 80 patients. J Clin Gastroenterol 1990;12:303-305.

12) Kaplan PB, Gücer F, Sayin NC, Yüksel M, Yüce MA, Yardim T. Maternal serum cytokine levels in women with hyperemesis gravidarum in the first trimester of pregnancy. Fertil Steril 2003;79:498-502.

13) [No authors listed]. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol 2019;133:e1-e25.

14) Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169:1000-1006.

15) Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-167.

16) Martin JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006;195:914-934.

17) Sibai BM, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-799.

18) Giles C, Inglis TC. Thrombocytopenia and macrothrombocytosis in gestational hypertension. Br J Obstet Gynaecol 1981;88:1115-1119.

19) Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989;321:351-356.

20) Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Vācāmonico A, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989;321:357-362.

21) Roberge S, Nicolaides K, Demers S, Hyett J, Challett N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017;216:110-120.e6.

22) Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017;216:121-128.e2.

23) Knight M, Duley L, Henderson-Smarty DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2002;2:CD000492.

24) Martin JN Jr, Owens MY, Keiser SD, Parrish MR, Tam Tam KB, Brewer JM, et al. Standardized Mississippi Protocol treatment of 190 patients with HELLP syndrome: slowing disease progression and preventing new major maternal morbidity. Hypertens Pregnancy 2012;31:79-90.

25) Grand’maison S, Sauvé N, Weber F, Dagenais M, Durand M, Mahone M. Haptic rupture in hemolysis, elevated liver enzymes, and low platelets syndrome. Obstet Gynecol 2012;119:617-625.

26) Zarrinpar A, Farmer DG, Ghobrial RM, Lipshutz GS, Gu Y, Hiatt JR, et al. Liver transplantation for HELLP syndrome. Am Surg 2007;73:1013-1016.

27) Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P, UK Obstetric Surveillance System. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008;57:951-956.

28) Fesenmeier MF, Coppage KH, Lambers DS, Barton JR, Sibai BM. Acute fatty liver of pregnancy in 3 tertiary care centers. Am J Obstet Gynecol 2005;192:1416-1419.

29) Ko H, Yoshida EM. Acute fatty liver of pregnancy. Can J Gastroenterol 2006;20:25-30.

30) Sims HF, Brackett JC, Powell CK, Treem WR, Hale DE, Bennett MJ, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995;92:841-845.

31) Isaacs JD Jr, Sims HF, Powell CK, Bennett MJ, Hale DE, Treem WR, et al. Maternal acute fatty liver of pregnancy associated with fetal triglycerine protein deficiency: molecular characterization of a novel maternal mutant allele. Pediatr Res 1996;40:393-398.

32) Goel A, Ramakrishna B, Zachariah U, Ramachandran J, Eapen CE, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

33) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

34) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

35) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

36) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

37) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

38) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

39) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

40) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

41) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.

42) Ockner S, Brunt E, Cohn SM, Kurian G, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut 2011;60:138-139.
40) Al Inizi S, Gupta R, Gale A. Fetal tachyarrhythmia with atrial flutter in obstetric cholestasis. Int J Gynecol Obstet 2006;93:53-54.
41) Ataalla WM, Ziada DH, Gaber R, Ossman A, Bayomy S, Elemary BR. The impact of total bile acid levels on fetal cardiac function in intrahepatic cholestasis of pregnancy using fetal echocardiography: a tissue Doppler imaging study. J Matern Fetal Neonatal Med 2016;29:1445-1450.
42) Sanhal CY, Kara O, Yucel A. Can fetal left ventricular modified myocardial performance index predict adverse perinatal outcomes in intrahepatic cholestasis of pregnancy? J Matern Fetal Neonatal Med 2017;30:911-916.
43) Williamson C, Gorelik J, Eaton BM, Lab M, de Swiet M, Korchev Y. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci (Lond) 2001;100:363-369.
44) Williamson C, Miragoli M, Sheik Abdul Kadir S, Abu-Hayyeh S, Papacleovoulou G, Geenes V, et al. Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy. Dig Dis 2011;29:58-61.
45) Sheik Abdul Kadir SH, Miragoli M, Abu-Hayyeh S, Moskovich AV, Xie Q, Keitel V, et al. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS One 2010;5:e9689.
46) Wikström Shemer EA, Stephansson O, Thurisson M, Thorsell M, Ludvigsson JF, Marschall HU. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: a population-based cohort study. J Hepatol 2015;63:456-461.
47) Dixon PH, Wadsworth CA, Chambers J, Donnelly J, Cooley S, Buckley R, et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2014;109:76-84.
48) Dixon PH, van Mil SW, Chambers J, Strautnieks S, Thompson RJ, Lammert F, et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009;58:537-544.
49) Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-531.
50) Basq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012;143:1492-1501.
51) Chappell CA, Krans EE, Bunge K, Macio I, Bogen D, Scarsi KK, et al. A phase 1 study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus [Abstract]. In: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, MA. Abstract 87.
52) Mandimika C, Ogbuagu O. Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV. BMJ Case Rep 2019;12:pii.e230529.
53) AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-1492.
54) U.S. Preventive Services Task Force. Draft recommendation statement. Hepatitis C virus infection in adolescents and adults: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/hepatitis-c-scree ning1. Published August 2019. Accessed October 2019.
55) Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101:556-560.
56) Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-1278.
57) Eckert D,Margin1. Published August 2019. Accessed October 2019.
58) Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-1278.
59) Eckert D, C. Published August 2019. Accessed October 2019.
60) Eckert D, C. Published August 2019. Accessed October 2019.
61) Eckert D, C. Published August 2019. Accessed October 2019.
62) Eckert D, C. Published August 2019. Accessed October 2019.
63) Eckert D, C. Published August 2019. Accessed October 2019.
64) Eckert D, C. Published August 2019. Accessed October 2019.
65) Eckert D, C. Published August 2019. Accessed October 2019.
66) Eckert D, C. Published August 2019. Accessed October 2019.
67) Eckert D, C. Published August 2019. Accessed October 2019.
68) Eckert D, C. Published August 2019. Accessed October 2019.
69) Eckert D, C. Published August 2019. Accessed October 2019.
70) Eckert D, C. Published August 2019. Accessed October 2019.
71) Eckert D, C. Published August 2019. Accessed October 2019.
72) Eckert D, C. Published August 2019. Accessed October 2019.
73) Eckert D, C. Published August 2019. Accessed October 2019.
74) Eckert D, C. Published August 2019. Accessed October 2019.
75) Eckert D, C. Published August 2019. Accessed October 2019.
76) Eckert D, C. Published August 2019. Accessed October 2019.
77) Eckert D, C. Published August 2019. Accessed October 2019.
78) Eckert D, C. Published August 2019. Accessed October 2019.
79) Eckert D, C. Published August 2019. Accessed October 2019.
80) Eckert D, C. Published August 2019. Accessed October 2019.
81) Eckert D, C. Published August 2019. Accessed October 2019.
82) Eckert D, C. Published August 2019. Accessed October 2019.
83) Eckert D, C. Published August 2019. Accessed October 2019.
84) Eckert D, C. Published August 2019. Accessed October 2019.
85) Eckert D, C. Published August 2019. Accessed October 2019.
86) Eckert D, C. Published August 2019. Accessed October 2019.
87) Eckert D, C. Published August 2019. Accessed October 2019.
88) Eckert D, C. Published August 2019. Accessed October 2019.
89) Eckert D, C. Published August 2019. Accessed October 2019.
90) Eckert D, C. Published August 2019. Accessed October 2019.
91) Eckert D, C. Published August 2019. Accessed October 2019.
92) Eckert D, C. Published August 2019. Accessed October 2019.
93) Eckert D, C. Published August 2019. Accessed October 2019.
94) Eckert D, C. Published August 2019. Accessed October 2019.
95) Eckert D, C. Published August 2019. Accessed October 2019.
96) Eckert D, C. Published August 2019. Access...
75) De Souza LR, Berger H, Retnakaran R, Vlachou PA, Maguire JL, Nathens AB, et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol 2016;111:665-670.

76) Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease. Am J Gastroenterol 2016;111:658-664.

77) Hagström H, Höijer J, Ludvigsson JF, Bottai M, Ekbom A, Hultcrantz R, et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int 2016;36:268-274.

78) Carson MP. Society for maternal and fetal medicine workshop on pregnancy as a window to future health: clinical utility of classifying women with metabolic syndrome. Semin Perinatol 2015;39:284-289.

79) Russell MA, Criago SD. Cirrhosis and portal hypertension in pregnancy. Semin Perinatol 1998;22:156-165.

80) Pajor A, Lehoczky D. Pregnancy and extrahepatic portal hypertension. Review and report on the management. Gynecol Obstet Invest 1998;22:156-165.

81) Britton RC. Pregnancy and esophageal varices. Am J Surg 1982;143:421-425.

82) Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int 2010;30:275-283.

83) Hagström H, Höijer J, Marschall HU, Williamson C, Heneghan MA, Westbrook RH, et al. Outcomes of pregnancy in mothers with cirrhosis: a national population-based cohort study of 1.3 million pregnancies. Hepatol Commun 2018;2:1299-1305.

84) Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk, stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310-335.

85) Savage C, Patel J, Lepe MR, Lazarre CH, Rees CR. Transjugular intrahepatic portosystemic shunt creation for recurrent gastrointestinal bleeding during pregnancy. J Vasc Interv Radiol 2007;18:902-904.

86) Ingraham CR, Padia SA, Johnson GE, Easterling TR, Liou IW, Kanal KM, et al. Transjugular intrahepatic portosystemic shunt placement during pregnancy: a case series of five patients. Cardiovasc Intervent Radiol 2015;38:1205-1210.

87) Westbrook RH, Yeoman AD, O’Grady JG, Harrison PM, Devlin J, Heneghan MA. Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. Clin Gastroenterol Hepatol 2011;9:694-699.

88) Gonsalkorala ES, Cannon MD, Lim TY, Penna L, Williamson C, Heneghan MA. Non-invasive markers (ALBI and APRI) predict pregnancy outcomes in women with chronic liver disease. Am J Gastroenterol 2019;114:267-275.

89) Ammon FJ, Kohlhaas A, Elshaaawty O, Mueller J, Bruckner T, Sohn C, et al. Liver stiffness reversibly increases during pregnancy and independently predicts preeclampsia. World J Gastroenterol 2018;24:4393-4402.